Hays AG, et al. - Herein, patients with stable coronary artery disease (CAD) were assessed for changes in coronary endothelial function (CEF) following treatment with febuxostat, a potent xanthine oxidase (XO) inhibitor. Findings demonstrated that febuxostat-induced XO inhibition was although well tolerated and lowered serum urate, it failed to improve the primary endpoint of the study, CEF measured using magnetic resonance imaging after 6 weeks of treatment. As concluded, no significant improvement in impaired CEF can be achieved in this patient population by short-term inhibition of XO.